The status of axillary lymph nodes (ALN) remains an important prognostic factor that provides valuable information about overall survival to help guide adjuvant treatment decisions, as well as predict the axillary stage and help in making treatment decisions. For breast cancer patients, SLN-CEUS with body surface markers before surgery can define the pathway of LCs and measure the depth and number of SLNs. It may help to determine whether LNs are metastatic. However, it should be used as a complement of the blue dye method before surgery.